share_log

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65

Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65

Canaccord Genuity 維持對 CervoMed 的買入,將目標股價上調至 65 美元
Benzinga ·  04/08 07:37

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and raises the price target from $50 to $65.

Canaccord Genuity分析師蘇曼特·庫爾卡尼維持CervoMED(納斯達克股票代碼:CRVO)的買入並將目標股價從50美元上調至65美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論